Fact-checked by Grok 2 weeks ago

Genmab

Genmab A/S is a Danish biotechnology company founded in 1999 and headquartered in Valby, Copenhagen, specializing in the discovery, development, and commercialization of innovative antibody therapeutics for the treatment of cancer and other serious diseases. The company was established by a team including Florian Schönharting and initially focused on human antibody technologies, emerging as a spin-off from Medarex to advance antibody-based treatments in oncology. Over its history, Genmab has expanded its operations internationally, with key subsidiaries in the United States (including a major facility in Plainsboro, New Jersey), the Netherlands (Utrecht), Japan (Tokyo), and China (Suzhou). Genmab's proprietary technologies, such as DuoBody and HexaBody platforms, enable the creation of differentiated bispecific and multispecific antibodies designed to enhance efficacy and safety in treating complex diseases. The company's includes both proprietary and partnered programs, with a strong emphasis on but also extending to and other therapeutic areas. Notable approved products developed in collaboration include Darzalex (), a CD38-targeting for marketed by Janssen, which has generated significant sales milestones exceeding hundreds of millions in royalties for Genmab, and Arzerra (), approved for . Genmab has achieved key milestones, such as its 2000 on the Stock Exchange, which raised DKK 1.56 billion and marked one of Europe's largest biotech IPOs at the time, and early partnerships like its development collaboration with . More recently, the company has formed broad alliances, including a multi-product collaboration with for bispecific antibodies and a discovery partnership with argenx to advance therapies in and , sharing costs and profits. In , Genmab acquired ProfoundBio to bolster its antibody-drug conjugate technologies, and in September 2025, announced its acquisition of Merus N.V. to expand its late-stage pipeline. Through these efforts, Genmab continues to drive innovation in , with an expanding clinical and a commitment to transforming patient outcomes in areas of high unmet need.

Technology

Proprietary antibody platforms

Genmab's proprietary antibody platforms represent innovative approaches to enhance the therapeutic potential of monoclonal antibodies, focusing on bispecific targeting, effector function optimization, and precise . These technologies build upon natural antibody to create molecules with improved specificity, potency, and stability, originating from research initiated in the early following the company's founding in 1999. The platforms were developed through systematic exploration of antibody structure-function relationships, with the first DuoBody filed in , marking a key milestone in bispecific antibody production. The DuoBody platform enables the generation of stable bispecific antibodies capable of simultaneous to two distinct targets, leveraging a controlled Fab-arm exchange (cFAE) mechanism inspired by the natural half-antibody exchange observed in IgG4 antibodies. In this process, two parental IgG1 monoclonal antibodies—each with specific mutations in the CH1 and Cκ constant domains for compatibility—are mixed under mild reducing conditions, causing dissociation into heavy-light chain half-antibodies that reassemble into a single bispecific IgG1 molecule with high efficiency and purity. This technology supports various formats, including DuoBody-CD3, which facilitates T-cell redirection by engaging CD3 on T cells alongside a tumor-associated , promoting targeted immune without the need for complex heterodimerization or linker . The platform's versatility allows rapid production at bench scale or levels, making it broadly applicable for generating dual-targeting therapeutics. In September 2025, Genmab acquired Merus, adding the Biclonics® platform, which enables the creation of multispecific antibodies with differentiated for enhanced tumor targeting and immune . The HexaBody platform enhances antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) by promoting the formation of ordered antibody hexamers on target cell surfaces upon antigen binding. This is achieved through targeted mutations in the Fc domain, such as E430G, which strengthen non-covalent Fc-Fc interactions, enabling up to six IgG molecules to cluster efficiently and recruit immune effectors more potently than monomeric antibodies. Hexamerization amplifies C1q binding for CDC initiation and boosts natural killer cell engagement for ADCC, providing a 100-fold or greater increase in potency in preclinical models compared to standard IgG1 antibodies. The platform's design maintains the antibody's native structure until target engagement, minimizing off-target effects and supporting applications in oncology and autoimmune diseases. HexElect extends the HexaBody technology for site-specific conjugation in antibody-drug conjugates (ADCs), allowing precise attachment of cytotoxic payloads to predefined sites on the antibody to optimize drug-antibody ratios and . By combining dual HexaBody molecules that target complementary antigens on the same , the ensures selective activation and only to cells expressing both targets, reducing systemic while enhancing . This engineering approach facilitates uniform conjugation at or glycans, improving stability and bystander killing in heterogeneous tumors. The DuoHexaBody platform integrates the bispecific targeting of DuoBody with the hexamerization-enhanced effector functions of HexaBody, producing antibodies that bind two targets while forming stable hexamers to amplify ADCC and CDC. Target-mediated clustering triggers enhanced interactions, leading to superior immune recruitment and , as demonstrated in preclinical studies where DuoHexaBody constructs showed markedly increased potency over monospecific or non-hexamerizing bispecifics. This combination enables novel modalities, such as biparatopic antibodies that engage multiple epitopes on a single for deeper modulation.

Therapeutic applications and innovations

Genmab's antibody platforms are primarily applied in oncology, targeting both hematological malignancies and solid tumors through precise antigen engagement to enhance immune-mediated tumor cell destruction. In hematological cancers, such as relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, the company's bispecific antibodies target CD20 on malignant B-cells to recruit T-cells for cytotoxicity, demonstrating durable responses in heavily pretreated patients. For solid tumors, Genmab develops antibody-drug conjugates (ADCs) and bispecifics that address overexpressed antigens like EGFR and cMet, as seen in investigational programs for head and neck squamous cell carcinoma and other advanced cancers, where dual targeting improves tumor penetration and efficacy. Additionally, ADCs targeting folate receptor alpha in ovarian and endometrial cancers deliver cytotoxic payloads selectively to tumor cells, achieving antitumor activity in platinum-resistant settings with manageable safety profiles; as of August 2025, rinatabart sesutecan (Rina-S) received FDA Breakthrough Therapy Designation, with a third Phase 3 trial initiated in November 2025. Beyond , Genmab has explored applications in autoimmune disorders through platforms like DuoBody for bispecific T-cell redirection and early CD20-targeted antibodies such as , approved for . Preclinical data for DuoBody-CD3xCD20 demonstrated potent B-cell depletion in non-human primates, supporting potential use in depleting pathogenic B-cells in conditions like while aiming to preserve immune ; a 2023 partnership with argenx leverages DuoBody for programs. Key innovations include the development of subcutaneous bispecific antibodies, which significantly reduce administration time from hours for intravenous infusions to minutes, improving patient convenience and clinic efficiency without compromising efficacy. , a CD3xCD20 bispecific, exemplifies this by enabling at-home or outpatient dosing after initial cycles, with phase 3 data confirming high complete response rates in B-cell lymphomas. For ADCs, Genmab's integration of proprietary linker technologies from partnerships enhances and site-specific conjugation, leading to improved intracellular and reduced off-target compared to earlier generations. These advancements, including HexElect for co-engaged hexamerization, allow for conditional immune activation on dual-antigen-positive cells, amplifying potency while minimizing systemic effects. Genmab's research and development has evolved since 2015 toward next-generation multispecific antibodies and ADCs, moving beyond traditional monoclonals to address tumor heterogeneity and resistance. This shift, initiated through expanded DuoBody collaborations and augmented by the 2025 Merus acquisition, has resulted in over 20 active programs as of November 2025, including bispecific T-cell engagers and targeted cytotoxin across indications. The focus on multispecific formats has accelerated late-stage advancements, with multiple phase 3 trials underway, reflecting a strategic emphasis on modalities that combine immune with precise delivery for broader therapeutic impact.

History

Founding and early development

Genmab A/S was established in February 1999 in , , as a of Medarex, Inc., with initial backing from BankInvest Biomedical and led by Florian Schönharting, who served as the initial managing director. Genmab licensed Medarex's HuMAb-Mouse technology to develop fully human . The company was founded with an initial focus on developing human monoclonal targeting cancer, leveraging in antibody engineering to address unmet needs in therapeutics. Co-founders included Donald L. Drakeman and Jan G. J. van de Winkel, the latter joining as () in 1999 to lead research efforts. Under van de Winkel's guidance, early (R&D) centered on the HuMax platform, which utilized Medarex's HuMAb-Mouse technology to generate fully human , minimizing risks associated with therapeutic use. To support its nascent operations, Genmab raised seed capital through venture investments and strategic alliances shortly after founding, culminating in a landmark (IPO) on the Copenhagen Stock Exchange in October 2000, which raised approximately DKK 1.6 billion (about €210 million). This funding enabled the expansion of facilities, including the establishment of laboratories in and a U.S. presence in , by 2001 to facilitate operations and business development. By 2003, Genmab advanced its first clinical candidate, HuMax-CD20 (later known as ), filing an (IND) application with the U.S. FDA in December for a Phase I/II trial in non-Hodgkin's patients. As a young biotechnology firm, Genmab faced typical early-stage challenges, including constrained financial resources and the need to prioritize efficient R&D amid a competitive landscape. These limitations steered the company toward a focused on antibody engineering and platform optimization rather than broad-spectrum , allowing it to build a pipeline through targeted collaborations and technology licensing up to the mid-2000s.

Key milestones and product approvals

Genmab's collaboration with Janssen Biotech on , marketed as Darzalex, marked a pivotal advancement in the company's commercial trajectory. In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture, and commercialize , receiving an upfront payment of $55 million and potential payments exceeding $1 billion. The U.S. (FDA) granted accelerated approval for Darzalex in November 2015 as a monotherapy for patients with who had received at least three prior lines of therapy. Subsequent label expansions included combination regimens in 2016, frontline use for transplant-ineligible patients in 2018, a subcutaneous formulation (Darzalex Faspro) in May 2020, and frontline transplant-eligible settings in 2019, broadening its application across treatment paradigms. Beyond Darzalex, Genmab achieved several other regulatory successes through partnerships. In August 2020, the FDA approved Kesimpta (ofatumumab), a subcutaneous formulation licensed to Novartis, for the treatment of relapsing forms of multiple sclerosis in adults, leveraging Genmab's original HuMax-CD20 antibody technology initially developed for oncology. The following year, in September 2021, the FDA granted accelerated approval to Tivdak (tisotumab vedotin), co-developed with Seagen (now part of Pfizer), for adult patients with recurrent or metastatic cervical cancer after at least two prior systemic therapies, based on the company's DuoBody antibody-drug conjugate platform. In May 2023, Epkinly (epcoritamab-bysp), co-developed with AbbVie using Genmab's DuoBody technology, received accelerated FDA approval for relapsed or refractory diffuse large B-cell lymphoma after two or more prior lines of systemic therapy. By 2023, these efforts contributed to FDA approvals for medicines incorporating Genmab's proprietary antibody technologies, including earlier products like Arzerra (ofatumumab) in 2009. Key financial and operational milestones underscored Genmab's growth during this period. The company began receiving from Darzalex sales in , with Janssen reporting net sales of $572 million that year, generating DKK 458 million in income for Genmab. reached DKK 5,366 million in 2019, driven primarily by escalating Darzalex and milestone payments, reflecting the drug's expanding . Genmab's ordinary shares have been listed on since October 2000, with American Depositary Shares listing on the Global Select Market in July 2019 to enhance U.S. investor access. These developments facilitated a shift to sustained profitability starting in , supported by robust streams. By 2022, Genmab established dedicated U.S. commercial teams to support launches like Epkinly, strengthening its North American operations and transitioning toward greater direct commercialization capabilities.

Acquisitions and strategic expansions

In April 2024, Genmab announced its acquisition of ProfoundBio, a clinical-stage company focused on antibody-drug conjugates (), for $1.8 billion in cash, subject to adjustments for net debt and transaction expenses. The deal, completed on May 21, 2024, provided Genmab with full rights to ProfoundBio's three clinical-stage ADC candidates, including Rina-S (rinatabart sesutecan), a next-generation ADC targeting NaPi2b for ovarian and other solid tumors, along with ProfoundBio's proprietary ADC technology platform. This acquisition strengthened Genmab's capabilities in ADC development, particularly for solid tumor indications, by integrating advanced linker-payload technologies designed to improve therapeutic indices. To support its growing U.S. operations, Genmab expanded its presence in with a new facility in Plainsboro, announced in March 2024 and officially opened in June 2025 at the Princeton Forrestal Innovation Center. The site, spanning over 135,000 square feet across three floors, serves as a key hub for , , and commercial activities, with an investment of approximately $32.6 million for renovations. In , Genmab continued to bolster its operations in , , post-2020, by joining the Utrecht Science Park's biotech and adding significant and in adjacent buildings to foster innovation in antibody engineering. These expansions contributed to Genmab's global workforce growing to 2,682 employees by the end of 2024, surpassing 2,000 team members and reflecting accelerated hiring in R&D and operations. Genmab's most significant inorganic growth move came in September 2025, when it agreed to acquire Merus N.V., a Dutch biotechnology company specializing in bispecific antibodies, for approximately $8 billion in an all-cash transaction at $97 per share—a 41% premium to Merus' closing price prior to the announcement. The deal, announced on September 29, 2025, includes a tender offer for 100% of Merus' shares, with closure anticipated in the first quarter of 2026, pending regulatory approvals and other customary conditions. It integrates Merus' triclonics platform and late-stage assets, such as petosemtamab, a bispecific antibody in phase 3 trials for head and neck squamous cell carcinoma (HNSCC), enhancing Genmab's wholly owned pipeline in solid tumors. To finance the Merus acquisition, Genmab launched a comprehensive debt financing package in November 2025, including a proposed private offering of $1.5 billion in senior secured notes due 2032, $1 billion in senior unsecured notes due 2033, and a $2 billion senior secured facility, totaling around $5.5 billion in non-convertible debt. This funding, combined with existing cash reserves, supports the transaction while maintaining Genmab's investment-grade credit profile, as rated 'BB(EXP)' by Fitch with a stable outlook. Strategically, these moves aim to diversify Genmab's pipeline into solid tumors and accelerate development of differentiated assets like petosemtamab through integrated R&D efforts, with plans for post-acquisition synergy in bispecific and technologies to drive a shift toward a more independent, wholly owned model.

Leadership and governance

Executive committee

The Executive Committee of Genmab A/S, comprising nine senior leaders as of November 2025, oversees the company's operational strategy, , , and global expansion in therapeutics. This team drives Genmab's focus on and innovations, leveraging collective expertise in , clinical development, and to support the company's growth following major milestones like the announced 2025 acquisition of Merus N.V. Jan G. J. van de Winkel, Ph.D., serves as President and , a role he has held since co-founding Genmab in 1999. With a background in tumor from his prior positions at Medarex and the University of , van de Winkel directs overall strategy, R&D priorities, and partnerships, emphasizing antibody engineering platforms like DuoBody and HexaBody. His leadership has guided Genmab through its evolution from a startup to a Copenhagen-headquartered biotech with over 2,000 employees. Anthony Pagano is Executive and , having joined Genmab in and advanced to in March 2020. Pagano manages financial operations, , and capital allocation amid post-IPO expansion, playing a pivotal role in financing the proposed $8 billion all-cash acquisition of Merus announced in September 2025, which is expected to bolster Genmab's bispecific antibody pipeline. Key members include Judith Klimovsky, M.D., Executive Vice President and Chief Development Officer since 2017, who leads global clinical development with a focus on programs, drawing from over 20 years in R&D at firms like . Tahi Ahmadi, M.D., is Executive Vice President and , overseeing medical affairs and regulatory . Brad Bailey serves as Executive Vice President and Chief Commercial Officer, directing commercialization efforts for approved products like . Chris Cozic is Executive Vice President and Chief People Officer, managing and talent acquisition. Martine J. van Vugt, Ph.D., is Executive Vice President and , guiding long-term strategic initiatives. Rayne Waller is Executive Vice President and Chief TechOps Officer, responsible for technical operations and manufacturing. In July 2025, Greg Mueller joined as Executive Vice President, , and Chief Legal Officer, effective July 1, replacing Birgitte Stephensen, who retired on August 1 after serving in legal roles since 2003; Mueller's appointment strengthens legal support for ongoing acquisitions and management. This adjustment maintained the committee at nine members, ensuring continuity in governance amid Genmab's strategic expansions.

Board of directors

Genmab's consists of 10 members as of 2025, with six independent directors and a collective expertise spanning , pharmaceuticals, finance, and . The board includes employee-elected representatives to ensure alignment with internal operations and strategic priorities in and development. Deirdre P. Connelly serves as Chair, bringing over 30 years of experience in pharmaceutical leadership, including product launches and global governance roles from her time as a Merck executive. Anders Gersel Pedersen, a non-independent director with more than 30 years in pharma and biotech, contributes deep knowledge of product pipelines and regulatory affairs. In March 2025, three new employee-elected members joined for three-year terms: Martin Schultz, Senior Director of Clinical Operations, offering insights into operational execution; Mijke Zachariasse, Ph.D., Vice President and Head of Antibody Research, providing expertise in innovative antibody platforms; and Michael Kavanagh, Senior Director and Head of Strategic Engagement in Oncology Marketing, enhancing perspectives on mergers, acquisitions, and commercial strategy in oncology. Jan G.J. van de Winkel, the company's President and CEO, also serves on the board, bridging executive and oversight functions. The board operates through specialized committees, including the Audit and Finance Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Scientific Committee, which oversee financial reporting, executive pay, director nominations, and R&D innovation. Following the announcement of Genmab's proposed $8 billion acquisition of Merus in September 2025, the board has placed increased emphasis on (ESG) principles alongside oversight of potential pipeline integration and technological advancements in bispecific antibodies. The board reflects diversity with 40% women and representation from four nationalities across the and , including Danish, American, German/Swiss, and members, fostering a perspective on biotech .

Approved products

Co-developed and proprietary medicines

Genmab's co-developed and medicines represent key approved therapies where the company plays a leading role in development and commercialization. These products leverage Genmab's innovative technologies to address unmet needs in , particularly in hematologic and gynecologic cancers. Epkinly (epcoritamab-bysp), a bispecific T-cell engaging antibody utilizing Genmab's DuoBody technology to target CD3 and CD20, received accelerated approval from the U.S. Food and Drug Administration (FDA) on May 19, 2023, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low-grade lymphoma, after two or more lines of systemic therapy. The European Medicines Agency (EMA) granted marketing authorization for epcoritamab (branded as Tepkinly) on September 25, 2023, for the same indication in adults with relapsed or refractory DLBCL after at least two prior systemic therapies. As the first subcutaneous bispecific antibody approved for this patient population, Epkinly offers convenient outpatient administration via subcutaneous injection, reducing treatment burden compared to intravenous options. Genmab co-develops Epkinly with AbbVie and co-commercializes it in the United States and European Union, sharing profits equally while retaining rights in other regions. Tivdak (tisotumab vedotin-tftv), an incorporating Genmab's HuMax-TF directed against (TF) conjugated to a (MMAE) payload via a cleavable linker, was initially granted accelerated approval by the FDA on September 20, 2021, for adult patients with recurrent or metastatic with disease progression on or after . This approval was converted to full approval on April 29, 2024, based on confirmatory data from the phase 3 innovaTV 301 trial demonstrating improved overall survival compared to . The approved Tivdak on March 31, 2025, for the treatment of adults with recurrent or metastatic previously treated with , marking it as the first authorized in the EU for this indication. Genmab co-developed Tivdak with (acquired by in 2023) under a 50:50 cost- and profit-sharing agreement, with leading global commercialization efforts. These medicines have driven significant commercial growth for Genmab, with combined global net sales of and reaching $453 million in the first nine months of 2025, a 54% increase from $295 million in the same period of 2024. To support this expansion, Genmab established its U.S. commercial organization in 2023 following 's approval, enabling direct promotion and sales in key markets.

Licensed and partnered medicines

Genmab's licensed and partnered medicines represent a significant portion of its revenue through agreements with pharmaceutical partners who handle , , and . These arrangements stem from Genmab's early technologies, out-licensed to larger biopharma companies, enabling streams while Genmab retains rights to royalties and milestones. By 2025, six out-licensed products based on Genmab's innovations had received regulatory approvals, collectively driving over 80% of the company's through royalties. A flagship example is Darzalex (daratumumab), an anti-CD38 for . Genmab licensed to Janssen Biotech (a subsidiary) in 2012 under an exclusive worldwide agreement, granting Janssen rights to develop and commercialize the asset. The U.S. FDA first approved Darzalex in 2015 for relapsed or , with subsequent approvals for additional indications, including frontline and newly diagnosed settings, expanding its global use. A subcutaneous formulation was approved in 2020, enhancing patient convenience through co-formulation with Halozyme's ENHANZE technology. By 2025, Darzalex net sales had reached an estimated $13.7 billion annually, with Genmab receiving tiered royalties in the low double-digits on global net sales, projected at $2.3-2.4 billion for the year; these royalties are partially offset by Genmab's share of Janssen's payments to Halozyme. Additionally, Genmab had received approximately $850 million in milestone payments from Janssen by 2020, with potential for further developmental and commercial milestones up to $165 million. Another key licensed product is Kesimpta (ofatumumab), an anti-CD20 monoclonal antibody for relapsing multiple sclerosis (MS). Genmab out-licensed ofatumumab to Novartis in 2015, building on an earlier 2009 agreement with GlaxoSmithKline for the intravenous version (Arzerra); Novartis focused on a self-administered subcutaneous formulation using Genmab's technology. The FDA approved Kesimpta in 2020 as a once-monthly injection, offering a differentiated profile with rapid B-cell depletion and long-term efficacy in reducing relapses and MRI lesions. Genmab earns tiered royalties in the low double-digits on global net sales, supplemented by milestone payments for regulatory and sales achievements, contributing to rising royalty income as Kesimpta sales grew post-launch. Among other licensed approvals, Tepezza (teprotumumab), an IGF-1R for thyroid eye disease, was out-licensed by Genmab to in 2005 and sub-licensed to , which commercialized it following FDA approval in 2020. Genmab receives mid-single-digit royalties on Tepezza net sales, providing steady revenue from this first-in-class therapy targeting active disease progression. Overall, Genmab's revenue model for these partnered medicines features tiered royalties typically up to the low double-digits, combined with upfront payments, milestones, and potential for additional economics, underscoring the long-term value of its antibody platforms in generating sustainable income exceeding $2.2 billion in royalties for the first nine months of 2025 alone.

Research and development

Proprietary pipeline

Genmab's proprietary pipeline encompasses investigational antibody-based therapeutics where the company holds primary development responsibility, emphasizing bispecific antibodies and antibody-drug conjugates (ADCs) for indications. As of late 2025, the portfolio includes approximately 10 programs, with five in phase 2 or later, reflecting a strategic shift toward fully owned assets following key acquisitions. These efforts prioritize formats and next-generation ADCs to enhance patient accessibility and therapeutic efficacy. Epcoritamab, a subcutaneous bispecific T-cell engager targeting CD3 and , represents a cornerstone of Genmab's proprietary expansions in hematologic malignancies. In August 2025, the phase 3 EPCORE FL-1 trial met its dual primary endpoints of overall response rate and in patients with relapsed/refractory , demonstrating a 95.7% response rate and a 79% reduction in the risk of disease progression or death when combined with rituximab and . The U.S. FDA accepted a supplemental biologics license application with , setting a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025. Ongoing trials further explore epcoritamab in (CLL), including the phase 1/2 EPCORE CLL-1 study evaluating its safety and efficacy in relapsed/refractory CLL and Richter's , as well as early investigations in solid tumors. Rina-S (rinatabart sesutecan), an acquired through Genmab's 2024 purchase of ProfoundBio, targets folate receptor alpha with a novel I inhibitor payload and a hydrophilic, protease-cleavable linker designed to minimize off-target . The program advanced to phase 3 in by late 2025, building on phase 1/2 data showing a 50% confirmed objective response rate in heavily pretreated patients at a follow-up of one year. Genmab plans additional phase 3 trials in and other gynecologic indications by year-end, supported by FDA Designation for advanced in August 2025. Beyond these leads, Genmab's proprietary efforts include early-stage bispecific antibodies targeting solid tumors, bolstered by Genmab's announced acquisition of Merus in September 2025, expected to close in the first quarter of 2026, which will integrate assets like petosemtamab—a bispecific antibody for head and neck —into the . Overall advancement has been accelerated by the 2024 acquisition of ProfoundBio and the pending 2025-2026 acquisition of Merus, enabling a focus on high-potential, wholly owned programs in next-generation ADCs and subcutaneous therapies.

Partnered pipeline programs

Genmab's partnered pipeline programs encompass several clinical-stage antibody therapeutics led by collaborators, leveraging the company's DuoBody technology and other innovations for indications. These efforts focus on advancing treatments in hematologic and solid tumors, with Genmab receiving royalties, milestones, and potential opt-in rights for co-development or commercialization. As of late 2025, key programs include combinations involving and , as well as bispecific antibodies from the pending Merus acquisition expected to be integrated into partner-led trials. Janssen, a Johnson & Johnson company, leads multiple phase 3 trials of daratumumab (Darzalex), a CD38-targeting monoclonal antibody co-developed with Genmab, in frontline multiple myeloma and amyloidosis settings. Notable examples include the AQUILA study, which demonstrated a 51% reduction in progression risk to active multiple myeloma or death in high-risk smoldering multiple myeloma, leading to FDA approval on November 6, 2025. The CEPHEUS trial confirmed daratumumab-based quadruplet therapy's superiority in progression-free survival for newly diagnosed multiple myeloma. Additionally, the phase 3 Majestec-3 trial showed that the combination of daratumumab with teclistamab (Tecvayli) improved progression-free and overall survival versus standard care in relapsed/refractory multiple myeloma, with results announced in October 2025. Over 10 daratumumab combination trials remain ongoing across various lines of therapy, highlighting Janssen's expansive development strategy. Merck leads the phase 3 LiGeR-HN1 (NCT06525220) evaluating petosemtamab, a bispecific antibody targeting and from Merus, combined with in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), initiated in early 2025 with interim data showing robust efficacy and durability. Upon completion of Genmab's announced acquisition of Merus in September 2025, expected to close in the first quarter of 2026, petosemtamab will advance further in these partner-led . A parallel phase 3 , LiGeR-HN2, assesses petosemtamab monotherapy versus investigator's choice in previously treated HNSCC. These efforts build on phase 2 results demonstrating promising response rates, positioning petosemtamab for potential immuno-oncology synergies. Other partnered programs include zenocutuzumab (from Merus pre-acquisition), a HER2xHER3 bispecific in phase 3 evaluation for NRG1 fusion-positive cancers. Merus initiated phase 3 targeting non-small cell and pancreatic ductal with NRG1 fusions, supported by phase 1/2 eNRGy data published in 2025 showing durable responses in 30% of patients across NRG1-positive solid tumors. leads phase 3 combinations of (Epkinly), a CD3xCD20 bispecific T-cell engager co-developed with Genmab, in earlier lines of B-cell malignancies; the EPCORE FL-1 met dual endpoints for in August 2025, with FDA review ongoing as of November 30, 2025. Approximately 10 programs are in phase 2 or later, including expansions of (Tivdak) with into additional indications, such as approvals in in March 2025 and ongoing in combination regimens. These partnerships drive potential milestones, including up to $165 million in additional payments from Janssen tied to regulatory and sales achievements, emphasizing Genmab's focus on immuno-oncology collaborations to accelerate patient access.

Partnerships and collaborations

Major strategic alliances

Genmab's major strategic alliances have centered on long-term collaborations with pharmaceutical companies to advance antibody-based therapies, particularly in , through shared , regulatory, and efforts. In August 2012, Genmab entered into a global license and development agreement with Janssen Biotech, Inc., granting Janssen an exclusive worldwide license to develop, manufacture, and commercialize , a targeting for and other indications. Under the terms, Genmab received an upfront payment of USD 55 million, with potential payments up to USD 1.1 billion based on development, regulatory, and sales achievements, in addition to tiered royalties on net sales. As of December 31, 2023, Genmab had received USD 910 million in payments from Janssen related to . The partnership has supported extensive clinical development, including combination regimens such as with , , and (approved in 2018), and ongoing expansions into frontline and newly diagnosed settings. Janssen leads global commercialization, while Genmab benefits from royalties, which formed the majority of Genmab's royalty income in 2024, driven by net sales of USD 11,670 million reported by . In June 2020, Genmab and announced a broad collaboration to co-develop and commercialize three early-stage bispecific programs, including (DuoBody-CD3xCD20), a T-cell engaging bispecific for B-cell malignancies, along with options for up to four additional targets. provided an upfront payment of USD 750 million to Genmab, with potential payments totaling up to USD 3.15 billion across the programs and tiered royalties ranging from 22% to 26% on net sales of outside the U.S. and . Genmab leads Phase 1 studies for , after which has opt-in rights for further development. The companies share costs and profits 50:50 for the specified programs. received accelerated FDA approval in May 2023 for relapsed or refractory after at least two prior therapies, followed by approval in June 2024 for relapsed or refractory . Since approval, Genmab and have jointly commercialized in the U.S. and , with Genmab booking U.S. sales and receiving royalties globally. In August 2017, Genmab and (then Seattle Genetics) established a co-development and commercialization partnership for , an antibody-drug conjugate targeting for solid tumors, including . The agreement stipulates 50:50 cost and profit sharing, with Genmab responsible for manufacturing the antibody component and Seagen handling conjugation and clinical supply. , marketed as Tivdak, received accelerated FDA approval in September 2021 for recurrent or metastatic following platinum-based , based on the Phase 2 innovaTV 204 trial demonstrating a 24% objective response rate. Genmab co-promotes Tivdak in the U.S., while (now under following its USD 43 billion acquisition in December 2023) leads global efforts. The partnership continues post-acquisition, supporting expanded development in other indications such as ovarian and endometrial cancers. In April 2023, Genmab and argenx entered a collaboration to jointly discover, develop, and commercialize novel therapies for applications in and . The partnership leverages Genmab's DuoBody technology and argenx's discovery capabilities, with the companies sharing development costs and profits equally. No upfront payment was disclosed, but the agreement includes potential milestone payments and royalties on net sales for resulting products. As of , the collaboration is in early stages, focusing on multiple to address unmet needs in autoimmune diseases and cancer.

Technology licensing and out-licensing

Genmab has actively out-licensed its proprietary antibody technologies, particularly the DuoBody platform for bispecific antibodies, to enable partners to develop novel therapeutics across various indications. In 2012, Genmab entered a broad research and collaboration agreement with Janssen Biotech, granting access to the DuoBody technology for up to 20 bispecific antibody programs in oncology and immunology, with an upfront payment of $3.5 million, potential development and regulatory milestone payments of up to approximately $175 million per program, and tiered royalties in the low to mid-single digits on net sales. Under this agreement, Janssen has exercised options on 11 programs, resulting in cumulative upfront and milestone payments exceeding $500 million across Genmab's DuoBody deals, including this collaboration. That same year, Genmab licensed the DuoBody platform to Novartis for two specific target combinations aimed at bispecific antibody development, receiving a $2 million upfront payment, with potential milestones up to $175 million and similar low-single-digit royalties. In 2015, Genmab expanded its DuoBody out-licensing by granting commercial rights to the platform for creating bispecific antibodies against two undisclosed targets, primarily for metabolic and cardiovascular diseases, with a $2 million upfront , potential milestones totaling $110 million, and royalties in the low double-digit range. For its HexaBody platform, which enhances through hexamerization, Genmab has pursued targeted out-licensing focused on specific applications. In 2019, Genmab signed an exclusive worldwide and option with Janssen for HexaBody-CD38, a next-generation CD38-targeting , providing Janssen an option for full development rights in exchange for a $35 million upfront , potential milestones $1.7 billion, and royalties in the mid-teens on net sales; however, Janssen declined to exercise the option in March 2025 following review of Phase 1/2 data. Complementing its out-licensing efforts, Genmab has strategically in-licensed complementary to bolster its engineering capabilities. In 2000, Genmab obtained a broad to Medarex's HuMAb- transgenic , which facilitates the generation of fully human monoclonal , in exchange for an equity stake in the company; this enabled the creation of Genmab's early HuMax portfolio, including HuMax-CD20 (). Genmab's technology licensing agreements generally feature upfront payments ranging from $2 million to $35 million, payments tied to preclinical, clinical, and commercial achievements, and royalties typically in the low-single to mid-teen percentages on net sales of resulting products. By 2025, these deals have supported more than 20 active programs in clinical development incorporating Genmab's technologies, generating over $200 million in annual revenue from non-major partnered products through milestones and royalties.

References

  1. [1]
    Our History | Genmab
    Genmab's history has been powered by a dedication to antibody-based therapeutics. Learn more about our key accomplishments, milestones and moments.<|control11|><|separator|>
  2. [2]
    Contact us | Genmab
    Genmab's general contact number is +45 7020 2728. Their Danish address is Carl Jacobsens Vej 30, 2500 Valby, Denmark. For medical info, request information.
  3. [3]
    Genmab: Home
    Genmab is an international biotech company specializing in antibody therapeutics for the treatment of cancer and other serious diseases.Careers · About · Our History · Resources
  4. [4]
    https://www.pharmexec.com/view/jan-van-de-winkel-antibody-ascension
  5. [5]
    Jan van de Winkel: Antibody Ascension | PharmExec
    Sep 17, 2024 · A little more than two years later, Genmab was founded as a European spin-off of Medarex—and the rest is history. Throughout his journey ...
  6. [6]
    Genmab - LinkedIn
    Oct 29, 2025 · We are an international biotech company committed to our goal of improving the lives of patients through innovative and differentiated antibody therapeutics.
  7. [7]
    All Genmab Office Locations - Glassdoor
    Rating 4.1 (152) Genmab has offices in Plainsboro, US; Ballerup, Copenhagen, and Utrecht; Suzhou, China; and Tokyo, Japan.
  8. [8]
    Genmab Celebrates Expanded Presence in Plainsboro
    Jun 27, 2025 · Genmab, an affiliate of Copenhagen-based Genmab AS, now occupies a total of 270,000 square feet at the park located at 777 Scudders Mill Road, ...
  9. [9]
    Our Structure Enables Scientific Innovation - Genmab US
    Genmab works in unique ways and is organized differently to bring innovative new thinking to antibody-based medicines.
  10. [10]
    Research and Development Pipeline - Genmab US
    Through our differentiated pipeline, we are exploring novel treatment options with unique potential to impact the lives of patients with cancer and other ...
  11. [11]
    An Overview of Genmab's Drug Pipeline | Therapeutic Areas
    Sep 8, 2023 · Genmab currently has two approved antibodies: Arzerra® (ofatumumab) for certain chronic lymphocytic leukemia indications and DARZALEX™ ( ...
  12. [12]
    Genmab - PharmaBoardroom
    Nov 5, 2015 · Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic ...<|separator|>
  13. [13]
    AbbVie and Genmab Announce Broad Oncology Collaboration
    Jun 10, 2020 · AbbVie and Genmab have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's early-stage investigational bispecific ...
  14. [14]
    Genmab and argenx Enter Partnership to Advance Antibody ...
    Apr 17, 2023 · Genmab and argenx will jointly discover, develop, and commercialize antibody therapies in immunology and oncology, sharing costs and profits, ...Missing: notable achievements<|control11|><|separator|>
  15. [15]
    Genmab to partner with Novartis on antibodies | Drug Discovery News
    Per the terms ofthe agreement, Genmab will create panels of bispecific antibodies to twodisease target combinations that Novartis has identified. All research ...
  16. [16]
    20 Years of Achievement in Antibody Science | Genmab US
    Genmab began as one of the only companies in the world focused on using human antibodies to treat cancer. Since then we've expanded into other serious diseases.
  17. [17]
    [PDF] Investor Fact Sheet As of Nov 6
    November 6, 2025. Certain product candidates in development with partners, as noted. For more information about our pipeline, visit www.Genmab.com/pipeline.
  18. [18]
    US-10597464-B2 - Heterodimeric Antibody Fc-containing Proteins ...
    Merck Patent GMBH. Title: Engineered Heterodimeric Protein Domains. WO-2008145140 ... Genmab, slideshow, 43 pages (2008). Genmab, "DuoBody platform, Genmab's ...
  19. [19]
    Efficient generation of stable bispecific IgG1 by controlled Fab-arm ...
    Mar 26, 2013 · The parental antibodies are mixed and subjected to controlled reducing conditions in vitro that separate the antibodies into HL half-molecules ...
  20. [20]
    DuoBody® | Biotechnology Platform - Genmab
    DuoBody® is Genmab's versatile platform technology for discovering and developing bispecific antibodies, also called dual-targeting molecules. Learn more.Missing: proprietary | Show results with:proprietary
  21. [21]
    [PDF] Genmab Announces DuoBody and HexaBody Platform ...
    Genmab's DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as ...Missing: HexElect DuoHexaBody<|control11|><|separator|>
  22. [22]
    A Novel Platform for the Potentiation of Therapeutic Antibodies ...
    Jan 6, 2016 · Potentiation of CDC Activity by Increased Hexamerization Is Broadly Applicable. Previously, we showed that antigen-bound IgG molecules ...
  23. [23]
    HexaBody®| Genmab
    HexaBody is Genmab's proprietary antibody platform that allows for the creation of potentially potent therapeutics by inducing antibody hexamer formation.
  24. [24]
    Antibody Technology Platforms - Genmab
    Our technology platforms harness the power of the human immune system. DuoBody, HexaBody, DuoHexaBody and HexElect build on natural antibody biology.Missing: proprietary | Show results with:proprietary
  25. [25]
    Unique Technology Platforms For Developing Antibody Medicines
    DuoHexaBody combines the strengths of two antibody technology platforms into one. DuoHexaBody antibodies have the dual-targeting (bispecific) ability of DuoBody ...Missing: proprietary | Show results with:proprietary
  26. [26]
    DuoHexaBody-CD37®, a novel biparatopic CD37 antibody ... - NIH
    Apr 28, 2020 · Here, we introduce DuoHexaBody-CD37, a novel CD37-targeted agent generated using an innovative approach that combines DuoBody and HexaBody ...
  27. [27]
    DuoHexaBody®| Genmab
    DuoHexaBody combines our DuoBody and HexaBody technologies, creating bispecific antibodies with target-mediated enhanced hexamerization.
  28. [28]
    Genmab Announces Updated Results from Phase 2 EPCORE ...
    Sep 3, 2025 · Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody® technology and administered subcutaneously. Genmab's ...
  29. [29]
    [PDF] Genmab Interim Report Q2 2025
    Aug 7, 2025 · GEN1160 is a CD70-targeted ADC created using Genmab's ADC technology. CD70 is a protein expressed on both solid tumors and hematological ...<|separator|>
  30. [30]
    Genmab Announces New Data Demonstrating Investigational ...
    Oct 18, 2025 · Rinatabart sesutecan (Rina-S; GEN1184) is an investigational ADC. It is composed of a novel human monoclonal antibody directed at folate ...Missing: TROP2 | Show results with:TROP2
  31. [31]
    [PDF] Better Antibodies By Design
    Nov 16, 2016 · Autoimmune disorders, Target: inflammatory mediators. JNJ ... B cell depletion Cynomolgus. Lymph Nodes. Page 19. 58%. 20%. 14%. 8%. 2016 ...
  32. [32]
    [PDF] GENMAB ANNOUNCES HUMAX-CD20 PROGRAM
    Antibodies in this program target the. CD20 antigen on B-cells and initially Genmab will focus on using the antibody for the treatment of Non Hodgkin's Lymphoma ...Missing: applications EGFR TROP2
  33. [33]
    Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met ...
    Aug 7, 2025 · Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody® technology and administered subcutaneously. Genmab's ...
  34. [34]
    Antibody-Drug Conjugates (ADCs) - Genmab
    Explore how antibody-drug conjugates selectively target cancer cells, combining targeted therapy with chemotherapy to improve treatment and reduce toxicity.
  35. [35]
    HexElect®| Genmab
    HexElect is a combination of two HexaBody molecules designed to work together. By selectively targeting cells that express targets for both antibodies.Missing: conjugation ADC
  36. [36]
    Genmab to Broaden and Strengthen Oncology Portfolio with ...
    Apr 3, 2024 · The acquisition will give Genmab worldwide rights to ProfoundBio's portfolio of next-generation ADCs, which consists of three clinical and ...
  37. [37]
    Genmab (United States) | Policy Commons
    Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical ...
  38. [38]
    Genmab | Company Overview & News - Forbes
    The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark. Read ...
  39. [39]
    Jan G. J. Van de Winkel Ph.D. | Executive Committee - Genmab
    Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company
  40. [40]
    Making the Most of Monoclonal Antibodies
    Genmab employs Medarex's HuMAb-Mouse® technology for creating fully human Mabs in transgenic mice. The HuMAb-Mouse platform produces IgG antibodies that are 100 ...
  41. [41]
    Initial public offering of Genmab A/S (DK) — DKK 1.6 billion
    October 2000. Carnegie acted as co-lead manager in the initial public offering of Genmab A/S on the Copenhagen Stock Exchange. Genmab A/S is a Danish ...<|control11|><|separator|>
  42. [42]
    [PDF] Genmab is a product development com - AnnualReports.com
    During 2001, we have established a US- based clinical trial team and in addition a part of the global business development team is located in Princeton, New.
  43. [43]
    [PDF] GENMAB FILES IND FOR HUMAX-CD20 TO TREAT NON ...
    ... Phase I/II clinical trial using HuMax-CD20 to treat Non-Hodgkin's Lymphoma. Copenhagen, Denmark; December 19, 2003 – Genmab A/S (CSE: GEN) announced that it ...
  44. [44]
    [PDF] Annual Report
    To maximise the value of our integrated human antibody development capabilities, Genmab is form- ing partnerships with other companies to co-develop antibody.
  45. [45]
    The 5-Step Strategy That Saved Genmab From A Dire Outlook
    Dec 30, 2019 · Van de Winkel served as CSO since Genmab's inception in 1999 and worked as the head of research and preclinical development through April ...<|control11|><|separator|>
  46. [46]
    Janssen Biotech Announces Global License and Development ...
    Aug 30, 2012 · Genmab will grant Janssen an exclusive worldwide license to develop and commercialize daratumumab as well as a back-up CD38 human antibody.
  47. [47]
    Darzalex (daratumumab) FDA Approval History - Drugs.com
    Darzalex FDA Approval History. Last updated by Judith Stewart, BPharm on Sep 30, 2019. FDA Approved: Yes (First approved November 16, 2015)
  48. [48]
    FDA approves Novartis Kesimpta® (ofatumumab), the first and only ...
    Aug 20, 2020 · FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis.
  49. [49]
    Genmab and Seagen Announce FDA Accelerated Approval for ...
    Sep 20, 2021 · TIVDAK is approved under the FDA's Accelerated Approval Program based on tumor response and the durability of the response. Continued approval ...
  50. [50]
    EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First ...
    May 19, 2023 · EPKINLY is approved under the FDA's Accelerated Approval program based on response rate and durability of response. Continued approval for this ...
  51. [51]
    [PDF] Genmab Announces 2016 Net Sales Figures for DARZALEX ...
    Net sales of DARZALEX in 2016 totaled USD 572 million. •. Genmab will receive royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark ...
  52. [52]
    securities and exchange commission - SEC Filing - Genmab A/S
    On July 22, 2019, the public offering and listing of American Depository Shares (ADSs) on Nasdaq Global Select Market under the symbol “GMAB” was completed.
  53. [53]
    [PDF] Genmab Announces Financial Results for the First Half of 2016 and ...
    Apr 20, 2016 · Net sales of DARZALEX by Janssen were USD 209 million for the first half of 2016, resulting in royalty income of DKK 168 million. The first ...
  54. [54]
    Genmab Completes Acquisition of ProfoundBio
    May 21, 2024 · Genmab acquired ProfoundBio for USD 1.8 billion, gaining rights to three clinical candidates, including Rina-S, and ProfoundBio's ADC ...
  55. [55]
    Genmab to Broaden and Strengthen Oncology Portfolio with
    Apr 3, 2024 · Genmab will acquire ProfoundBio for USD 1.8 billion in cash, payable at closing (subject to adjustment for ProfoundBio's closing net debt and ...
  56. [56]
    Genmab expands U.S. footprint with Plainsboro facility | ROI-NJ
    Jul 1, 2025 · Genmab recently celebrated the grand opening of its expanded U.S. site at the Princeton Forrestal Innovation Center.
  57. [57]
    Genmab to expand in New Jersey in bid to boost Epkinly rollout
    Mar 28, 2024 · Genmab is expected to invest around $32.6 million to renovate and fit out the new office space in Plainsboro, New Jersey.
  58. [58]
    Success story - Genmab - ROM Invest - Utrecht Region
    So, we are going to add significant space in a new building next door – the Accelerator – a unique hub within Utrecht Science Park's innovation ecosystem.” Read ...Missing: expansions | Show results with:expansions
  59. [59]
    Genmab: Number of Employees 2019-2025 | GMAB - Macrotrends
    Genmab total employee count in 2024 was 2,682, a 21.69% increase from 2023. · Genmab total number of employees in 2023 was 2,204, a 32.77% increase from 2022.Missing: size | Show results with:size
  60. [60]
    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and ...
    Sep 29, 2025 · Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model · Company Announcement · COPENHAGEN, Denmark; ...
  61. [61]
    Genmab to acquire closely watched cancer drug in $8B Merus buyout
    Sep 29, 2025 · Per deal terms, Genmab will pay $97 per share in cash to acquire Merus, representing a 41% premium to the biotech's closing price on Friday of ...
  62. [62]
    Genmab pays $8B to buy Merus and phase 3-stage bispecific
    Genmab is continuing to build its pipeline of wholly owned cancer assets, this time paying $8 billion for Merus and its bispecific antibody.<|separator|>
  63. [63]
    https://ir.genmab.com/news-releases/news-release-details/genmab-announces-changes-its-executive-committee-0
  64. [64]
    https://ir.genmab.com/news-releases/news-release-details/genmab-commences-tender-offer-all-issued-and-outstanding-common
  65. [65]
    Genmab Announces Changes to its Executive Committee
    Jul 1, 2025 · Greg will join Jan and the rest of the Executive Committee, including Chief Medical Officer Dr. Tahi Ahmadi, Chief Commercial Officer Brad ...Missing: members | Show results with:members
  66. [66]
    Genmab Commences Tender Offer for All Issued and Outstanding ...
    Oct 21, 2025 · Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. · Media Release COPENHAGEN, Denmark; October 21, 2025.
  67. [67]
    Judith Klimovsky M.D. | Executive Committee - Genmab
    Dr. Klimovsky joined Genmab in 2017 and is a recognized drug developer with more than 20 years of experience in R&D leadership roles in big pharma.
  68. [68]
    GMAB.P - | Stock Price & Latest News | Reuters
    Martin Schultz: Non-Independent Director, Employee Elected. Mijke Zachariasse: Non-Independent Director, Employee Elected. Rolf K. Hoffmann: Independent ...Missing: members Mike
  69. [69]
    Passing of Genmab A/S' Annual General Meeting
    Mar 12, 2025 · At Genmab A/S' Annual General Meeting held today March 12, 2025, the Annual Report for 2024 was approved · Discharge was given to the Board of ...
  70. [70]
    [PDF] To the Shareholders of Genmab A/S February 13, 2025 ANNUAL ...
    Feb 13, 2025 · It is proposed to adopt the audited Annual Report 2024 and to grant discharge to the Board of Directors and the Executive Management. Re item 3 ...
  71. [71]
    New Members Elected to Genmab's Board of Directors
    Mar 21, 2025 · The newly elected board members are Martin Schultz, Senior Director, Clinical Operations, Mijke Zachariasse, Vice President, Head of Antibody Research ...
  72. [72]
    Board Committees and Charters - Genmab
    Genmab's Board of Directors has established and appointed Audit and Finance, Compensation, Nominating and Corporate Governance, and Scientific Committees.<|separator|>
  73. [73]
    [PDF] EPKINLY (epcoritamab-bysp) injection - accessdata.fda.gov
    EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large. B-cell lymphoma (DLBCL), not otherwise specified, including ...
  74. [74]
    AbbVie Announces European Commission Approval of TEPKINLY ...
    Sep 25, 2023 · TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for the treatment of this patient population in the European Union (EU ...
  75. [75]
    EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients ...
    Jun 27, 2024 · The US Food and Drug Administration (FDA) has approved EPKINLY (epcoritamab-bysp) for the treatment of adults with relapsed or refractory (R/R) follicular ...
  76. [76]
    FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervic
    Apr 29, 2024 · FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer. On April 29, 2024, the Food and Drug Administration granted ...
  77. [77]
    FDA Grants Full Approval for TIVDAK® to Treat Recurrent or ... - Pfizer
    Apr 29, 2024 · TIVDAK received accelerated approval from the U.S. FDA in September 2021 for adult patients with recurrent or metastatic cervical cancer with ...
  78. [78]
    TIVDAK® (tisotumab vedotin) Approved by European Commission ...
    Mar 31, 2025 · TIVDAK is the first and only ADC to be granted European Union (EU) marketing authorization for people living with recurrent or metastatic cervical cancer.
  79. [79]
    https://ir.genmab.com/static-files/835ff23e-32c4-4bf5-82a3-020c16aaa614
  80. [80]
    [PDF] Genmab Announces Financial Results for the First Nine Months of ...
    Nov 7, 2023 · Following the approval of EPKINLY in the U.S. on May 19, 2023, Genmab recognized net product sales of DKK 189 million through September 30, 2023 ...Missing: force | Show results with:force
  81. [81]
    Genmab at a Glance
    Genmab is an international biotechnology company that develops innovative antibody products to transform the treatment of cancer and other serious diseases.
  82. [82]
    genmab 2020 annual report - SEC.gov
    ... DARZALEX ® royalties achieved under our daratumumab collaboration with Janssen. Net sales of DARZALEX ® by Janssen were USD 4,190 million in 2020 compared ...
  83. [83]
    Novartis Kesimpta® six-year efficacy data show substantial benefits ...
    Apr 17, 2024 · First-line use of Kesimpta for up to six years provided long-term benefits, including fewer relapses, profoundly suppressed MRI lesion activity, and fewer ...Missing: royalties | Show results with:royalties
  84. [84]
    https://www.oncologypipeline.com/apexonco/genmab-takes-its-profound-buy-endometrial
  85. [85]
    Genmab Receives FDA Breakthrough Therapy Designation for ...
    Aug 26, 2025 · By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody ...
  86. [86]
    Genmab takes its Profound buy into endometrial - Oncology Pipeline
    Sep 16, 2025 · Genmab has said it plans to have three phase 3 trials of its ProfoundBio-originated ADC rinatabart sesutecan under way by the end of 2025 ...Missing: TROP2 | Show results with:TROP2
  87. [87]
    https://www.jnj.com/media-center/press-releases/tecvayli-plus-darzalex-faspro-combination-regimen-significantly-improves-progression-free-survival-and-overall-survival-versus-standard-of-care
  88. [88]
    the randomized phase 3 CEPHEUS trial | Nature Medicine
    Feb 5, 2025 · Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes in newly diagnosed ...
  89. [89]
    TECVAYLI® plus DARZALEX FASPRO® combination regimen ...
    Oct 16, 2025 · First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as ...
  90. [90]
    Merus' Petosemtamab with Pembrolizumab Interim Data ...
    May 22, 2025 · Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC. May 22, 2025 at 5:30 PM ...Missing: Merck | Show results with:Merck
  91. [91]
    NCT06496178 | A Phase 3 Study to Evaluate Petosemtamab ...
    This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for ...Missing: Merck | Show results with:Merck
  92. [92]
    Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L ...
    May 28, 2025 · A global phase 3 trial, LiGeR-HN1 (NCT06525220), is ongoing to evaluate petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC.Missing: Merck | Show results with:Merck
  93. [93]
    Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer - Merus
    Feb 5, 2025 · Zenocutuzumab demonstrated durable efficacy in patients with advanced NRG1+ cancer, notably NSCLC and pancreatic adenocarcinoma, with a favorable safety ...
  94. [94]
    Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
    Feb 5, 2025 · The efficacy and safety of zenocutuzumab, a bispecific antibody against HER2 and HER3, in patients with NRG1 fusion–positive solid tumors are ...
  95. [95]
    Genmab's Tivdak approved in Japan for advanced cervical cancer
    Mar 28, 2025 · Genmab has received approval from Japan's Ministry of Health, Labour and Welfare for its Tivdak to treat cervical cancer.<|separator|>
  96. [96]
    [PDF] Genmab Enters Broad Collaboration with Janssen Biotech, Inc. for ...
    Jul 12, 2012 · “Since the introduction of our DuoBody platform in 2010, we have believed in its potential to become the preferred technology for next ...
  97. [97]
    [PDF] Genmab Achieves $3 Million Milestone in DuoBody Platform ...
    Janssen has optioned 11 programs out of a total of 20 programs under the bispecific DuoBody platform collaboration with Genmab. Including the collaboration ...
  98. [98]
    Novartis Pays Genmab $2M to Tap into Bispecific Antibody ...
    Jun 4, 2012 · Genmab will develop panels of DuoBody antibodies against two Novartis target combinations. Novartis is paying Genmab $2 million up front as ...
  99. [99]
    [PDF] Genmab Enters Commercial License Agreement with Novo Nordisk ...
    ... 2015 – Genmab A/S (OMX: GEN) announced today it has entered an agreement to grant Novo Nordisk commercial licenses to use the DuoBody technology platform to ...
  100. [100]
    Genmab forms new alliance to develop CD38 antibody
    Jun 13, 2019 · Genmab has signed a global licence and option agreement with Janssen ... Janssen will also pay a 20% royalty on sales of HexaBody-CD38 ...<|control11|><|separator|>
  101. [101]
    Genmab axes anti-CD38 antibody after losing J&J support
    Mar 10, 2025 · J&J opts out of licensing Genmab's Darzalex challenger after look at phase 1/2 data · J&J bags $150M option on Genmab's Darzalex successor · After ...
  102. [102]
    Genmab completes financing round; company to ... - | BioWorld
    June 19, 2000 ... One of the investors was Medarex, which had previously granted Genmab a broad license to its HuMAb-Mouse(R) technology in exchange for equity.
  103. [103]
    Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry
    Apr 3, 2024 · Genmab said Wednesday it's agreed to pay $1.8 billion for ProfoundBio, gaining access to the biotechnology startup's technology for developing ...
  104. [104]
    Pipeline - Genmab
    Our pipeline of antibody therapeutics includes investigational medicines in clinical development, and in-house and partnered pre-clinical programs.Missing: autoimmune | Show results with:autoimmune
  105. [105]
    https://ir.genmab.com/news-releases/news-release-details/genmab-announces-financial-results-nine-months-2025